For the first time, an investigator initiated phase 1b study tested the combination of the PARP inhibitor olaparib, and the AKT inhibitor capivasertib, and showed this combination was well tolerated and achieved durable responses in [more]
PARP inhibitors are the first class of drugs to exploit a new concept in oncology – synthetic lethality. Alexandra Leary explains the rationale, reviews the trial evidence and clinical experience, and looks to their future [more]
Most people carrying harmful BRCA mutations only find out after they are diagnosed with cancer, and often not even then. Population screening is costly and the results can be hard to interpret. But should we [more]
Over the past decade, genetic testing for rare inherited mutations, such as BRCA1 and BRCA2 mutations, has been successfully incorporated into clinical practice. Next-generation sequencing of cancer-susceptibility genes and entire tumour genomes has transformed cancer [more]
As more is learned about inherited genetic mutations that make cancers more likely, there is an acute need to give those who live with the mutated genes clear information and accurate advice. Download full article
Selected reports edited by Janet Fricker Download full article
A recent study has shown that women with BRCA mutations are as likely to achieve local control with breast-conserving treatment as women without mutations, but have increased long-term risk of ipsilateral and contralateral breast cancer. [more]